Milestone PBAC victory finally lands

MSD has finally got its long-sought recommendation from the PBAC for a broad cancer listing for Keytruda and the more than 30 indications approved by the TGA.

At its December Intracycle Meeting the PBAC recommended a broad listing of Keytruda for the treatment of advanced or metastatic cancers, after MSD addressed the Committee's concerns from the July 2025 submission regarding access for patients with rare cancers, concerns which had left MSD 'bewildered'.

"This milestone decision takes us one step closer to broadening and accelerating affordable access to immunotherapy for eligible Australians with advanced cancers, particularly rare and less common types," MSD Australia and New Zealand Managing Director, Chifumi Umeda, said.